ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Intellia Therapeutics has acquired Rewrite Therapeutics, a developer of DNA-writing technologies, for $45 million plus $155 million in potential milestone payments. Intellia is developing gene-editing therapies based on the CRISPR-Cas9 editing system. The company says Rewrite’s DNA-writing tools, including CRISPR-Cas9-guided polymerases, could provide new ways to edit disease-causing genes.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X